56.62
+1.87%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bayer
Its shares trade on XETRA under the ticker BAYN.DE. It has been listed since 28 November 1997. It is a member of the DAX and Euro Stoxx 50. In the fiscal year to 31 December 2025, it reported revenue of €45.58bn and a net loss of €3.62bn. At that date it held total assets of €110.61bn and shareholders' equity of €25.95bn.
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Nov 1997
- Employees
- 99,841
- Website
- bayer.de ↗
Leadership
Pay as last reported
- Prof. Dr. Norbert WinkeljohannIndependent Member of the Supervisory Board, since 2018€510,000
- Mr. William AndersonChairman of the Management Board, Chief Executive Officer€8.8m
- Ms. Heike HausfeldVice Chairwoman of the Supervisory Board, Employee Representative, since 2017€347,000
- Mr. Wolfgang NicklChief Financial Officer, Member of the Management Board€3.6m
- Mr. Stefan OelrichMember of the Management Board, Head of the Pharmaceuticals Division€3.7m
- Ms. Haike PrinzMember of the Management Board, Chief Talent Officer and Labor Director€1.4m
- Mr. Rodrigo SantosMember of the Management Board, Head of the Crop Science€3.8m
- Mr. Julio TrianaMember of the Management Board, Head of the Consumer Health Division€3.3m
- Mr. Horst BaierIndependent Member of the Supervisory Board€331,000
- Ms. Ertharin CousinIndependent Member of the Supervisory Board, Shareholder Representative€248,000
- Ms. Colleen GogginsIndependent Member of the Supervisory Board, Shareholder Representative€227,000
- Ms. Kimberly MathisenIndependent Member of the Supervisory Board€201,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 85
- Environment
- 82
- Social
- 94
- Governance
- 79
- Direct emissions (scope 1)
- 1,880,000 t
- Energy emissions (scope 2)
- 1,650,000 t
- Value chain emissions (scope 3)
- 8,380,000 t
- Women in the workforce
- 42.1%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bayer AG has a diverse product portfolio, encompassing pharmaceuticals, consumer healthcare, agricultural products, and animal health. This diversification allows the company to generate revenue from multiple sources and reduces reliance on any single sector.
- The company has a strong global presence with operations in more than 90 countries. This allows Bayer to tap into different markets and benefit from localized strategies and customer preferences.
- Bayer boasts a strong research and development (R&D) capability, investing significantly in innovation. This enables the company to introduce new and improved products, keeping it competitive in the rapidly evolving healthcare and agricultural industries.
Weaknesses
- Bayer has faced several legal challenges related to its products, including lawsuits concerning alleged side effects of certain medications. These legal battles have had a negative impact on the company's reputation and financial performance.
- The company heavily relies on the pharmaceutical sector for a significant portion of its revenue. This concentration poses a risk as market dynamics, regulatory changes, or patent expirations can significantly impact financial stability.
- Bayer's acquisition of Monsanto, a controversial move due to concerns over genetically modified organisms (GMOs) and the potential environmental impact, has also raised questions about the company's sustainability practices and public perception.
Opportunities
- Growing demand for healthcare and agricultural products in emerging markets presents an opportunity for Bayer to expand its customer base and revenue streams. This includes addressing the rising healthcare needs of an aging global population.
- Advancements in technologies such as precision agriculture, gene editing, and digital health open doors for Bayer to develop innovative solutions, improve productivity, and enhance overall operational efficiency in its various sectors.
- Bayer can leverage its established brand and reputation to capitalize on the growing consumer interest in organic and sustainable products. Developing and promoting environmentally friendly solutions can lead to market differentiation and increased market share.
Threats
- Intense competition from both established pharmaceutical and agricultural companies, as well as emerging players, poses a threat to Bayer's market position. This includes the potential entry of generic and biosimilar products.
- Regulatory requirements and government policies can impact the company's ability to market and sell its products. Changes in regulations related to drug pricing, intellectual property, and environmental safety standards can create challenges for Bayer.
- Public scrutiny and consumer activism around controversial products, particularly in the agricultural sector, can harm the company's reputation and result in reduced sales or boycotts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.